Sudarshan S - Search Results

1

Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.

Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS. Hyer ML, et al. Among authors: sudarshan s. Cancer Biol Ther. 2002 Jul-Aug;1(4):401-6. doi: 10.4161/cbt.1.4.15. Cancer Biol Ther. 2002. PMID: 12432255

2

Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.

Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS. Hyer ML, et al. Among authors: sudarshan s. Cancer Gene Ther. 2003 Apr;10(4):330-9. doi: 10.1038/sj.cgt.7700576. Cancer Gene Ther. 2003. PMID: 12679806

3

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.

Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. Sudarshan S, et al. Cancer Gene Ther. 2005 Jan;12(1):12-8. doi: 10.1038/sj.cgt.7700746. Cancer Gene Ther. 2005. PMID: 15514684

4

Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma.

Parker R, Reeves HM, Sudarshan S, Wolff D, Keane T. Parker R, et al. Among authors: sudarshan s. Urology. 2005 Nov;66(5):1110. doi: 10.1016/j.urology.2005.06.074. Urology. 2005. PMID: 16286148 Review.

5

PRDM16 suppresses HIF-targeted gene expression in kidney cancer.

Kundu A, Nam H, Shelar S, Chandrashekar DS, Brinkley G, Karki S, Mitchell T, Livi CB, Buckhaults P, Kirkman R, Tang Y, Rowe GC, Wei S, Varambally S, Sudarshan S. Kundu A, et al. Among authors: sudarshan s. J Exp Med. 2020 Jun 1;217(6):e20191005. doi: 10.1084/jem.20191005. J Exp Med. 2020. PMID: 32251515 Free PMC article.

6

Metabolism of kidney cancer: from the lab to clinical practice.

Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Sudarshan S, et al. Eur Urol. 2013 Feb;63(2):244-51. doi: 10.1016/j.eururo.2012.09.054. Epub 2012 Sep 28. Eur Urol. 2013. PMID: 23063455 Free PMC article. Review.

7

Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?

Sonpavde G, Sudarshan S, Escudier B. Sonpavde G, et al. Among authors: sudarshan s. Eur Urol. 2014 Mar;65(3):585-6. doi: 10.1016/j.eururo.2013.09.001. Epub 2013 Sep 9. Eur Urol. 2014. PMID: 24044979 No abstract available.

8

Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes.

Liu NW, Khurana K, Sudarshan S, Pinto PA, Linehan WM, Bratslavsky G. Liu NW, et al. Among authors: sudarshan s. J Urol. 2010 May;183(5):1719-24. doi: 10.1016/j.juro.2010.01.010. Epub 2010 Mar 17. J Urol. 2010. PMID: 20299057 Free PMC article.

9

L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, Sudarshan S. Shim EH, et al. Among authors: sudarshan s. Cancer Discov. 2014 Nov;4(11):1290-8. doi: 10.1158/2159-8290.CD-13-0696. Epub 2014 Sep 2. Cancer Discov. 2014. PMID: 25182153 Free PMC article.

10

Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.

Sudarshan S, Pinto PA, Neckers L, Linehan WM. Sudarshan S, et al. Nat Clin Pract Urol. 2007 Feb;4(2):104-10. doi: 10.1038/ncpuro0711. Nat Clin Pract Urol. 2007. PMID: 17287871 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

116 results

Search Page